EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD

Yunqi Shi iD, Nan Ye iD, Guoqin Wang iD, Hong Cheng iD

Clinical Journal of the American Society of Nephrology · 2026-03 · 21 (3) · 401-413

DOI: 10.2215/cjn.0000000928 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.01.2026. Verfasst von Yunqi Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Endothelin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Anzhen Hospital High Level Research Funding, Beijing Municipal Hospital Scientific Research Cultivation Plan, Beijing Hospital Management Center's Youth Talent Training "Young Seedlings" Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Endothelin receptor antagonists should be applied for patients with CKD whose proteinuria and high risk of kidney function decline remains insufficiently controlled. We recommend that endothelin A receptor-selective endothelin receptor antagonists should be preferable for patients with CKD with consideration for combination therapy with sodium-glucose cotransporter-2 inhibitors.

Background

Endothelin receptor antagonists (ERAs) are considered a potential effective treatment to reduce proteinuria and protect kidney function for patients with CKD; however, they may cause fluid retention. We conducted this meta-analysis to quantify the efficacy and safety of ERAs in CKD.

Methods

We searched Cochrane Library, Ovid Medline, and Ovid Embase for randomized controlled trials up to January 2025. Continuous and dichotomous data were reported as standardized mean differences (SMDs) with 95% confidence intervals (CIs) and risk ratios (RRs) with 95% CIs, respectively.

Results

Fourteen trials enrolling 6412 patients were included. Compared with the control group, ERAs decreased the risk of ESKD (RR=0.76, 95% CI [0.61 to 0.96]), reduced the urine protein-to-creatinine ratio (SMD=−0.56, 95% CI [−0.78 to −0.35]) and urine albumin-to-creatinine ratio (SMD=−0.64, 95% CI [−0.75 to −0.53]), achieved more frequent complete proteinuria remission (RR=2.61, 95% CI [1.84 to 3.71]) and partial proteinuria remission (RR=1.51, 95% CI [1.32 to 1.73]), slowed the decline of eGFR in the subgroup with a follow-up duration of at least 1 year (SMD=0.18, 95% CI [0.04 to 0.32]), improved the chronic eGFR slope (SMD=0.15, 95% CI [0.01 to 0.30]), and decreased systolic BP (SMD=−0.53, 95% CI [−0.76 to −0.30]) and diastolic BP (SMD=−0.78, 95% CI [−1.18 to −0.38]). Although the risk was increased in B-type natriuretic peptide (SMD=0.08, 95% CI [0.01 to 0.16]) and body weight (SMD=0.15, 95% CI [0.01 to 0.29]), ERAs did not increase the incidence of edema, fluid retention, or heart failure. The risk of hypotension was higher with ERAs compared with the control group (RR=1.92, 95% CI [1.36 to 2.70]).

Conclusion

These findings suggest that ERAs may reduce proteinuria, prevent kidney disease progression, and lower BP in individuals with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicEndothelin Receptor AntagonistsHumansRandomized Controlled Trials as TopicProteinuriaSodium-Glucose Transporter 2 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

CKDproteinuria

Substanzen

Endothelin Receptor AntagonistsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Yunqi Shi, Nan Ye, Guoqin Wang, Hong Cheng

Förderung

  • Beijing Anzhen Hospital High Level Research Funding
  • Beijing Municipal Hospital Scientific Research Cultivation Plan
  • Beijing Hospital Management Center's Youth Talent Training "Young Seedlings" Program
  • Beijing Hospital Management Center's Youth Talent Training “Young Seedlings” Program

Zitieren

APA

Shi, Y., Ye, N., Wang, G., & Cheng, H. (2026). Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD. Clinical Journal of the American Society of Nephrology, 21(3), 401-413. https://doi.org/10.2215/cjn.0000000928

Vancouver

Shi Y, Ye N, Wang G, Cheng H. Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD. Clinical Journal of the American Society of Nephrology. 2026;21(3):401-413. doi:10.2215/cjn.0000000928

BibTeX
@article{Shi2026,
  author = {Shi, Yunqi and Ye, Nan and Wang, Guoqin and Cheng, Hong},
  title = {Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {401--413},
  doi = {10.2215/cjn.0000000928}
}
Kostenlos starten →